Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack received a Notice of Allowance from the USPTO for a patent application covering its implantable continuous blood glucose monitoring (CBGM) platform. The allowance adds to three patents issued in late 2025, expanding protection for the intravascular sensing lead and electronics assembly used in the fully implantable system.
Key figures
- Existing patents 2025
- 3
- Sensor longevity years
- 3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.